Figure 1. CONSORT Flow-chart of the clinical trial, with reason for exclusion of assessed subjects and for subjects that did not concluded the study.

180 hypercholesterolaemic subjects were assessed for eligibility

93 subjects were excluded
78 no NAFLD
1 for metastatic HCC
4 for other medical reasons
10 declined to participate

87 subjects fulfilled inclusion criteria and were randomised

43 subjects were assigned to and received tocotrienols

13 subjects assigned to tocotrienols did not complete the study
8 withdrew from the study
3 were excluded for protocol violation
2 missed final USG

30 subjects assigned to tocotrienols completed the study and underwent baseline & final USG

44 subjects were assigned to and received placebo

10 subjects assigned to placebo did not complete the study
6 withdrew from the study
2 were excluded for protocol violation
2 missed final USG

34 subjects assigned to placebo completed the study and underwent baseline & final USG

HCC = Hepatocellular carcinoma; USG = ultrasonography examination